Carmat SA
PAR:ALCAR
Intrinsic Value
Carmat SA engages in the developing of implantable orthotropic and biocompatible artificial heart. [ Read More ]
The intrinsic value of one ALCAR stock under the Base Case scenario is 24.99 EUR. Compared to the current market price of 4.25 EUR, Carmat SA is Undervalued by 83%.
Valuation Backtest
Carmat SA
Run backtest to discover the historical profit from buying and selling ALCAR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Carmat SA
Current Assets | 42.4m |
Cash & Short-Term Investments | 8m |
Receivables | 5.1m |
Other Current Assets | 29.3m |
Non-Current Assets | 10.6m |
Long-Term Investments | 613k |
PP&E | 10m |
Other Non-Current Assets | 71k |
Current Liabilities | 15.6m |
Accounts Payable | 9.6m |
Accrued Liabilities | 5.9m |
Other Current Liabilities | 18k |
Non-Current Liabilities | 64.5m |
Long-Term Debt | 57.6m |
Other Non-Current Liabilities | 6.8m |
Earnings Waterfall
Carmat SA
Revenue
|
2.8m
EUR
|
Cost of Revenue
|
-33.8m
EUR
|
Gross Profit
|
-31m
EUR
|
Operating Expenses
|
-21.5m
EUR
|
Operating Income
|
-52.5m
EUR
|
Other Expenses
|
-1.3m
EUR
|
Net Income
|
-53.9m
EUR
|
Free Cash Flow Analysis
Carmat SA
ALCAR Profitability Score
Profitability Due Diligence
Carmat SA's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Carmat SA's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
ALCAR Solvency Score
Solvency Due Diligence
Carmat SA's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Carmat SA's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALCAR Price Targets Summary
Carmat SA
According to Wall Street analysts, the average 1-year price target for ALCAR is 14.13 EUR with a low forecast of 9.09 EUR and a high forecast of 18.9 EUR.
Shareholder Return
ALCAR Price
Carmat SA
Average Annual Return | -7% |
Standard Deviation of Annual Returns | 45.77% |
Max Drawdown | -92% |
Market Capitalization | 123.9m EUR |
Shares Outstanding | 29 142 400 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Carmat SA engages in the developing of implantable orthotropic and biocompatible artificial heart. The company is headquartered in Velizy-Villacoublay, Ile-De-France and currently employs 160 full-time employees. The company went IPO on 2010-07-07. The firm is developing an orthotopic and biocompatible artificial heart which works like a natural heart and which is hydraulically activated. The firm formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels and Blood Institute, Laboratoire de Recherche Biochirurgicale and others. As of December 31, 2011, a company MATRA DEFENSE held a 30.57% stake in the Company’s shareholdings.
Contact
IPO
Employees
Officers
The intrinsic value of one ALCAR stock under the Base Case scenario is 24.99 EUR.
Compared to the current market price of 4.25 EUR, Carmat SA is Undervalued by 83%.